查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1627874

嗜伊红性食道炎治疗市场：预测（2025-2030）

Eosinophilic Esophagitis Disease Treatment Market - Forecasts from 2025 to 2030
出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 140 Pages | 商品交期: 最快1-2个工作天内

价格
简介目录

预计嗜伊红性食道炎治疗市场在预测期内将以8.15%的复合年增长率成长，从2025年的504,625,000美元增加到2030年的745,096,000美元。

嗜伊红性食道炎(EoE) 是一种过敏性发炎性疾病，涉及嗜酸性粒细胞（一种白血球）。主要症状包括胃灼热、胸痛和吞嚥困难。目前还没有治疗 EOE 的主要药物，有几种食物可以引起 EOE，包括贝类、鱼露和蚝油。

全球气喘和过敏患者数量的增加预计将推动全球嗜伊红性食道炎治疗市场的发展。患有EoE的患者主要患有过敏性鼻炎、食物过敏、气喘等其他疾病。美国气喘和过敏基金会在报告中指出，约76%的EoE患者有食物过敏，70%有过敏性鼻炎，51%有气喘。此外，41% 的人患有异位性皮肤炎，16% 的人患有大肠激躁症。

嗜伊红性食道炎治疗市场的地理前景：

  • 预计北美地区在预测期内复合年增长率最高。

这种疾病在美国的盛行率不断上升，是未来几年 EoE 治疗需求增加的主要原因之一。例如，国家罕见疾病组织 (NORD) 在 2024 年 3 月发表了一篇关于嗜伊红性食道炎的论文，指出如果以美国人口为标准，美国10 万人中有 56.7 人患有嗜酸性粒总合嗜伊红性食道炎。此外，过去 20 年来，美国成人和儿童的 EoE 病例几乎翻了一番。因此，此类统计数据预计将在未来几年推动嗜伊红性食道炎治疗市场的发展。

此外，EoE 治疗的核准数量不断增加预计也将对未来几年的市场成长产生积极影响。例如，2024年1月，美国食品药物管理局（FDA）核准Dupixent®（dupilumab）用于治疗1岁以上儿童的EoE。此次核准延长了核准核准2022 年 5 月对适用于 12 岁及以上、体重 40 公斤的 EoE 的初步批准。 FDA 对 Dupixent 的这种扩大适应症进行了优先审查，表明该药物能够有效、安全地治疗这种罕见疾病。因此，此类产品的推出是预测期内市场成长的主要动力之一。

此外，预计该国医疗保健支出的增加将在预测期内推动市场成长。例如，根据美国医疗保险和医疗补助服务中心（美国 Medical Services）的数据，2021年人均医疗保健支出为12,914美元，医疗保健支出总额为43亿美元。到 2022 年，这一数字将增加至医疗保健总支出 45 亿美元，人均医疗保健支出达 13,493 美元。因此，人均医疗保健支出的增加预计也将对预测期内嗜伊红性食道炎治疗市场的成长产生积极影响。

为什么要购买这份报告？

  • 富有洞察力的分析：获得涵盖关键和新兴地区的深入市场洞察，重点关注客户细分、政府政策和社会经济因素、消费者偏好、行业和其他子区隔。
  • 竞争格局：了解世界主要企业采取的策略策略，并了解透过正确的策略渗透市场的潜力。
  • 市场趋势和驱动因素：探索动态因素和关键市场趋势以及它们将如何影响未来的市场发展。
  • 可行的建议：利用洞察力做出策略决策，在动态环境中发现新的业务流和收益。
  • 受众广泛：对于新兴企业、研究机构、顾问、中小企业和大型企业有用且具有成本效益。

它有什么用？

产业和市场考量、机会评估、产品需求预测、打入市场策略、地理扩张、资本投资决策、法律规范与影响、新产品开发、竞争影响

调查范围

  • 2022年至2030年历史资料与预测
  • 成长机会、挑战、供应链前景、法规结构、客户行为和趋势分析
  • 竞争定位、策略和市场占有率分析
  • 各国收益成长和预测细分市场和区域分析
  • 公司概况（尤其是主要趋势）

嗜伊红性食道炎治疗市场分为以下几个部分：

依产品类型

  • 仿单标示外药物
  • Budesonide口服悬浮液
  • FluticasoneODT
  • 美泊利单抗
  • 瑞利珠单抗
  • 贝那利珠单抗
  • 度匹鲁单抗
  • Omalizumab

按分销管道

  • 医院药房
  • 零售药房
  • 网路药房

按地区

  • 北美洲
  • 美国
  • 加拿大
  • 墨西哥
  • 南美洲
  • 巴西
  • 阿根廷
  • 其他的
  • 欧洲
  • 德国
  • 法国
  • 英国
  • 西班牙
  • 其他的
  • 中东/非洲
  • 沙乌地阿拉伯
  • UAE
  • 其他的
  • 亚太地区
  • 中国
  • 日本
  • 印度
  • 韩国
  • 印尼
  • 其他的

目录

第一章简介

  • 市场概况
  • 市场定义
  • 调查范围
  • 市场区隔
  • 货币
  • 先决条件
  • 基准年和预测年时间表
  • 相关人员的主要利益

第二章调查方法

  • 研究设计
  • 调查过程
  • 资料检验

第三章执行摘要

  • 主要发现
  • 分析师观点

第四章市场动态

  • 市场驱动因素
  • 市场限制因素
  • 波特五力分析
  • 产业价值链分析

第五章嗜伊红性食道炎治疗市场：产品平臺

嗜伊红性食道炎治疗市场：依产品类型

  • 介绍
  • 仿单标示外药物
  • Budesonide口服悬浮液
  • FluticasoneODT
  • 美泊利单抗
  • 瑞利珠单抗
  • 贝那利珠单抗
  • 度匹鲁单抗
  • Omalizumab

第七章嗜伊红性食道炎治疗市场：依通路分类

  • 介绍
  • 医院药房
  • 零售药房
  • 网路药房

第八章嗜伊红性食道炎治疗市场：按地区

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 南美洲
    • 巴西
    • 阿根廷
    • 其他的
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 其他的
  • 中东/非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 其他的
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 韩国
    • 印尼
    • 其他的

第九章竞争环境及分析

  • 主要企业及策略分析
  • 新兴企业和市场盈利
  • 合併、收购、协议和合作
  • 竞争对手仪表板

第十章 公司简介

  • Ellodi Pharmaceuticals
  • AstraZeneca Plc
  • Bristol-Myers Squibb Co
  • GlaxoSmithKline Plc
  • Sanofi
  • Takeda Pharmaceutical Company Limited
  • Pfizer
  • Landos Biopharma, Inc.
  • DBV Technologies
  • Calypso Biotech
  • Revolo Biotherapeutics
  • Allakos Inc.
  • Regeneron Pharmaceutical
简介目录
Product Code: KSI061612287

The eosinophilic esophagitis disease treatment market is projected to grow at a CAGR of 8.15% over the forecast period, increasing from US$504.625 million in 2025 to US$745.096 million by 2030.

Eosinophilic esophagitis (EoE) is a type of allergic inflammatory disease that involves a white blood cell type, eosinophils. Its major symptoms include heartburn, chest pain, and difficulty in swallowing. There are no major medicines that can cure EOE, and multiple foods like shellfish, fish sauce, and oyster sauce can cause it.

The global increase in asthma and allergy cases is estimated to push the global eosinophilic esophagitis disease treatment market forward. The patients suffering from EOE majorly have other conditions like allergic rhinitis, food allergies, or asthma. The Asthma and Allergy Foundation of America, in its report, stated that about 76% of EOE patients have food allergy as a comorbid condition, 70% have Allergic rhinitis, and 51% have asthma. The comorbid condition prevalence of atopic dermatitis and irritable bowel syndrome are 41% and 16%, respectively.

Eosinophilic Esophagitis Disease Treatment Market Geographical Outlook:

  • The North American region is expected to propel with the highest CAGR in the projected period.

The rising prevalence of this disease in the United States is one of the major reasons for the increased demand for EoE treatment in the coming years. For instance, the National Organization for Rare Disorders, Inc. (NORD) which published an article in March 2024, on Eosinophilic Esophagitis, stated that standardized to the U.S. population it has been estimated that 56.7 per 1,00,000 people in the US are suffering from eosinophilic esophagitis disease, which makes a total of 1,52,152 cases in total. Additionally, in the past two decades in the U.S., the cases of EoE have almost doubled in both adults and children. Hence, such stats are anticipated to fuel the eosinophilic esophagitis disease treatment market in the coming years.

The rising drug approval for the treatment of this disease of also expected to have a positive impact on the market growth in the coming years. For instance, in January 2024, the Food and Drug Administration (FDA) in the United States approved Dupixent(R) (dupilumab) for treating EoE for children aged 1 year or older. This approval extends the initial FDA approval for EOE in May 2022 for patients aged 12 years and older and weighing 40 kg. The FDA evaluated Dupixent for this expanded indication under priority review, and this drug proved to have efficiently and safely treated this rare condition. Hence, these product launches are one of the main reasons for market growth in the projected period.

Additionally, the rising healthcare expenditure in the country is anticipated to fuel the market growth in the forecasted period. For instance, according to the U.S. Centers for Medicare & Medicaid Services, and American Medical Services, the per capita healthcare expenditure in 2021 was US$12,914 or US$4.3 billion in total spend in healthcare. This number increased to US$4.5 billion in total healthcare spending, and per capita spending of US$13,493 in 2022. Hence, in the projected period, rising per capita healthcare spending is also expected to positively impact the eosinophilic esophagitis disease treatment market growth.

Reasons for buying this report:-

  • Insightful Analysis: Gain detailed market insights covering major as well as emerging geographical regions, focusing on customer segments, government policies and socio-economic factors, consumer preferences, industry verticals, other sub- segments.
  • Competitive Landscape: Understand the strategic maneuvers employed by key players globally to understand possible market penetration with the correct strategy.
  • Market Drivers & Future Trends: Explore the dynamic factors and pivotal market trends and how they will shape up future market developments.
  • Actionable Recommendations: Utilize the insights to exercise strategic decision to uncover new business streams and revenues in a dynamic environment.
  • Caters to a Wide Audience: Beneficial and cost-effective for startups, research institutions, consultants, SMEs, and large enterprises.

What do businesses use our reports for?

Industry and Market Insights, Opportunity Assessment, Product Demand Forecasting, Market Entry Strategy, Geographical Expansion, Capital Investment Decisions, Regulatory Framework & Implications, New Product Development, Competitive Intelligence

Report Coverage:

  • Historical data & forecasts from 2022 to 2030
  • Growth Opportunities, Challenges, Supply Chain Outlook, Regulatory Framework, Customer Behaviour, and Trend Analysis
  • Competitive Positioning, Strategies, and Market Share Analysis
  • Revenue Growth and Forecast Assessment of segments and regions including countries
  • Company Profiling (Strategies, Products, Financial Information, and Key Developments among others)

Eosinophilic Esophagitis Disease Treatment Market is analyzed into the following segments:

By Product Type

  • Off-Label Drugs
  • Budesonide Oral Suspension
  • Fluticasone ODT
  • Mepolizumab
  • Reslizumab
  • Benralizumab
  • Dupilunab
  • Omalizumab

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

By Geography

  • North America
  • USA
  • Canada
  • Mexico
  • South America
  • Brazil
  • Argentina
  • Others
  • Europe
  • Germany
  • France
  • United Kingdom
  • Spain
  • Others
  • Middle East and Africa
  • Saudi Arabia
  • UAE
  • Others
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Indonesia
  • Others

TABLE OF CONTENTS

1. INTRODUCTION

  • 1.1. Market Overview
  • 1.2. Market Definition
  • 1.3. Scope of the Study
  • 1.4. Market Segmentation
  • 1.5. Currency
  • 1.6. Assumptions
  • 1.7. Base and Forecast Years Timeline
  • 1.8. Key Benefits for the Stakeholders

2. RESEARCH METHODOLOGY

  • 2.1. Research Design
  • 2.2. Research Process
  • 2.3. Data Validation

3. EXECUTIVE SUMMARY

  • 3.1. Key Findings
  • 3.2. Analyst View

4. MARKET DYNAMICS

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Supplier
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY PRODUCT PIPELINE

6. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY PRODUCT TYPE

  • 6.1. Introduction
  • 6.2. Off-Label Drugs
  • 6.3. Budesonide Oral Suspension
  • 6.4. Fluticasone ODT
  • 6.5. Mepolizumab
  • 6.6. Reslizumab
  • 6.7. Benralizumab
  • 6.8. Dupilumab
  • 6.9. Omalizumab

7. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY DISTRIBUTION CHANNEL

  • 7.1. Introduction
  • 7.2. Hospital Pharmacies
  • 7.3. Retail Pharmacies
  • 7.4. Online Pharmacies

8. EOSINOPHILIC ESOPHAGITIS DISEASE TREATMENT MARKET BY GEOGRAPHY

  • 8.1. Introduction
  • 8.2. North America
    • 8.2.1. USA
    • 8.2.2. Canada
    • 8.2.3. Mexico
  • 8.3. South America
    • 8.3.1. Brazil
    • 8.3.2. Argentina
    • 8.3.3. Others
  • 8.4. Europe
    • 8.4.1. Germany
    • 8.4.2. France
    • 8.4.3. United Kingdom
    • 8.4.4. Spain
    • 8.4.5. Others
  • 8.5. Middle East and Africa
    • 8.5.1. Saudi Arabia
    • 8.5.2. UAE
    • 8.5.3. Others
  • 8.6. Asia Pacific
    • 8.6.1. China
    • 8.6.2. Japan
    • 8.6.3. India
    • 8.6.4. South Korea
    • 8.6.5. Indonesia
    • 8.6.6. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

  • 9.1. Major Players and Strategy Analysis
  • 9.2. Emerging Players and Market Lucrativeness
  • 9.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 9.4. Competitive Dashboard

10. COMPANY PROFILES

  • 10.1. Ellodi Pharmaceuticals
  • 10.2. AstraZeneca Plc
  • 10.3. Bristol-Myers Squibb Co
  • 10.4. GlaxoSmithKline Plc
  • 10.5. Sanofi
  • 10.6. Takeda Pharmaceutical Company Limited
  • 10.7. Pfizer
  • 10.8. Landos Biopharma, Inc.
  • 10.9. DBV Technologies
  • 10.10. Calypso Biotech
  • 10.11. Revolo Biotherapeutics
  • 10.12. Allakos Inc.
  • 10.13. Regeneron Pharmaceutical